Exact Sciences Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Exact Sciences Bundle
Investor-ready Business Model Canvas for a leading molecular diagnostics innovator
Unlock the full strategic blueprint behind Exact Sciences's Business Model Canvas. This in-depth map shows how the company creates value through innovative diagnostics, commercial partnerships, and diversified revenue streams while spotlighting competitive advantages and key risks. Purchase the complete, editable canvas for section-by-section insights ideal for investor decks, strategic planning, or benchmarking.
Partnerships
Payer and insurer alliances
Reimbursement agreements with Medicare (coverage since 2014) and payers covering over 90% of commercial lives ensure broad access to Cologuard and precision oncology tests. These partnerships lower patient out-of-pocket costs and accelerate adoption. Joint value dossiers and outcomes data drive favorable policies, while multiyear payer contracts improve revenue visibility.
Healthcare provider networks
Primary care (about 70% of screening referrals), GI specialists and oncology clinics serve as critical referral sources for Exact Sciences tests. Co-developed clinical pathways with health systems and networks embed tests into standard care across hundreds of organizations. Targeted clinician education and streamlined sample logistics reduce ordering friction and speed result delivery. Key opinion leaders accelerate evidence adoption and drive guideline inclusion.
Laboratory and logistics partners
Exact Sciences leverages CLIA-certified labs and high-throughput partners to scale testing quality within the ~100 billion USD US clinical lab market in 2024, while cold-chain and courier networks ensure reliable sample transport. Integrated LIMS and interoperability trim turnaround times, and capacity partners enable spikes in demand and new-test launches.
Research institutions and biopharma
Research centers supply cohorts, biobanks and trial sites to validate biomarkers, enabling Exact Sciences to link diagnostics to targeted therapies with biopharma partners; in 2024 Exact Sciences reported roughly $3.3B revenue, supporting expanded RWE programs that strengthened clinical utility claims and yielded co-publications boosting credibility.
- Academic cohorts and biobanks
- Biopharma companion diagnostics
- RWE studies (2024 scale-up)
- Co-publications increase adoption
Regulatory and advocacy collaborations
Engagement with FDA, CMS, and guideline bodies aligns test development and reimbursement, leveraging Medicare coverage of Cologuard for beneficiaries 50–85 every 3 years. Patient advocacy groups such as American Cancer Society amplify awareness and adherence. Public health and policy partnerships drive population screening and support USPSTF screening guidance for ages 45–75.
- Medicare coverage: beneficiaries 50–85 every 3 years
- USPSTF: screening 45–75
- Advocacy: ACS partnership
Medicare coverage, payer reach >90%, primary care referrals ~70%, 2024 revenue $3.3B
Reimbursement deals (Medicare coverage since 2014; payers cover >90% commercial lives) and multiyear contracts drive access and revenue visibility. Referral partnerships (primary care ~70% of screening referrals) and health systems embed Cologuard into care. CLIA labs, couriers and biopharma RWE alliances scaled capacity—2024 revenue ~$3.3B.
| Metric | 2024 |
|---|---|
| Revenue | $3.3B |
| US lab market | $100B |
| Commercial lives covered | >90% |
| Primary care referrals | ~70% |
What is included in the product
Detailed Word Document
A comprehensive Business Model Canvas tailored to Exact Sciences that maps its nine core blocks—value propositions, customer segments, channels, revenue streams, key resources, activities, partners, cost structure, and customer relationships—against real-world diagnostics and molecular screening operations. Includes competitive advantages, SWOT-linked insights, and polished narratives ideal for investor presentations and strategic decision-making.
Customizable Excel Spreadsheet
High-level, editable Business Model Canvas for Exact Sciences that condenses its diagnostic and screening strategy into a one-page snapshot, saving hours of structuring while enabling quick comparisons, team collaboration, and fast deliverables for boardrooms or analysts.
Activities
Assay R&D and biomarker discovery
Continuous innovation across multi-target stool DNA (Cologuard), blood-based, and tissue assays drives Exact Sciences pipeline expansion; Cologuard showed 92% sensitivity and 87% specificity for colorectal cancer in pivotal validation.
Rigorous analytical validation programs confirm sensitivity and specificity benchmarks for each assay.
Advanced bioinformatics refines molecular signatures from large clinical datasets, while a growing IP portfolio secures competitive advantage.
Clinical trials and evidence generation
Prospective DeeP-C trial showed Cologuard sensitivity for colorectal cancer 92.3% and specificity 89.8%. Retrospective and real-world studies corroborate clinical validity and utility. Health-economics models demonstrate cost-effectiveness versus no screening; USPSTF 2021 included stool-based tests and CMS covers Cologuard for Medicare beneficiaries every 3 years.
Manufacturing and lab operations
High-throughput sample processing at Exact Sciences handles over 1 million clinical samples annually (2024), delivering reliable 24–72 hour turnaround for most workflows. Quality systems keep operations CLIA- and CAP-compliant across their clinical labs. Automation and robotics have improved yield and reduced analytical errors by roughly 30% while boosting throughput above 10,000 samples per day. Capacity planning and flexible shifts enable scaling for seasonality and demand spikes.
Commercial sales and medical education
Multi-channel field teams engage providers and payers to drive adoption and reimbursement for screening products; medical science liaisons disseminate peer-reviewed data to clinicians and institutions to support guideline inclusion. Patient outreach programs increase screening completion rates while digital campaigns bolster adherence and timely re-screening.
- Field teams: provider & payer engagement
- MSLs: peer-reviewed data dissemination
- Patient outreach: screening completion
- Digital campaigns: adherence & re-screening
Data integration and informatics
Data integration and informatics enable interoperability with EHRs and e-ordering to simplify clinician workflows, leveraging the fact that 96% of US hospitals use certified EHRs (ONC). Centralized data warehouses consolidate clinical and operational metrics, while AI risk-stratification models improve test performance and secure analytics support payer and provider reporting.
- Interoperability: EHR integration (96% hospital EHR adoption)
- Consolidation: centralized data warehouses for metrics
- AI: enhanced risk stratification and test accuracy
- Reporting: secure analytics for payers/providers
Assay R&D boosts screening: 92.3% sens / 89.8% spec, 24–72h TAT
Assay R&D (Cologuard, blood/tissue) drives pipeline; DeeP-C Cologuard sensitivity 92.3% / specificity 89.8%, CMS covers every 3 years. Labs processed >1,000,000 samples in 2024 with 24–72h TAT, CLIA/CAP; automation cut errors ~30% and supports >10,000/day. Field teams, MSLs, EHR integration (96% hospital EHR adoption) and AI enable adoption and payer reporting.
| Metric | 2024 |
|---|---|
| Samples processed | >1,000,000 |
| Cologuard Sens/Spec | 92.3% / 89.8% |
| TAT | 24–72h |
| Throughput | >10,000/day |
| EHR adoption | 96% |
Preview Before You Purchase
Business Model Canvas
The Business Model Canvas for Exact Sciences shown here is the actual deliverable, not a mockup. When you purchase, you’ll receive this same complete document—fully formatted and editable. Files are provided ready to use for analysis, presentation, and sharing.
Resources
Proprietary test portfolio
Cologuard and Oncotype DX form Exact Sciences core revenue drivers, with Cologuard having screened over 5 million patients and Oncotype DX delivering more than 2 million tests as of 2024. Pipeline blood-based screening assays aim to expand TAM into multi-cancer detection. Validated algorithms and assay chemistry are strategic, regulatable assets underpinning clinical utility. Strong brand equity and clinician awareness support market leadership and uptake.
CLIA/CAP-certified laboratories
Exact Sciences’ CLIA/CAP-certified centralized labs deliver consistent quality and scale; CAP accredits over 8,000 labs and CMS lists roughly 260,000 CLIA-certified entities (2024), underscoring rigorous standards. Capital-intensive instrumentation and automation create high barriers to entry, certified technologists ensure result reliability, and redundant CLIA/CAP sites support business continuity.
Clinical and regulatory expertise
Experienced clinical and regulatory teams at Exact Sciences manage trial design, FDA and global submissions, and compliance, supporting a 2024 commercial platform tied to $3.4B revenue. Health economics and outcomes research (HEOR) drives payer value dossiers and coverage, informing cost-effectiveness models used in negotiations. Robust quality and regulatory systems lower approval risk and, combined with active relationships with guideline bodies, accelerate adoption in clinical pathways.
Data assets and bioinformatics
Data assets and bioinformatics drive discovery and validation through large annotated datasets; Exact Sciences' Cologuard pivotal study reported colorectal cancer sensitivity 92.1% and specificity 86.6%, illustrating assay-performance benchmarks used for model training.
- Dataset benchmark: Cologuard CRC sensitivity 92.1% / specificity 86.6%
- Machine learning: enhances sensitivity/specificity on genomic and assay data
- Governance & interoperability: HIPAA/GDPR frameworks connect providers and protect privacy
Commercial network and brand
Exact Sciences leverages deep provider relationships that accelerate Cologuard adoption and integration into screening workflows, while payer contracts expanded in 2024 to cover an estimated >90% of insured lives, broadening access; patient engagement programs lift adherence and repeat testing rates, and strong brand recognition in cancer diagnostics drives clinician and patient preference.
- Provider relationships: faster uptake
- Payer coverage 2024: >90% insured lives
- Patient programs: higher adherence/repeat testing
- Brand: market leader in noninvasive CRC screening
Screening >5M, genomic tests >2M; 2024 revenue $3.4B, payer coverage >90%
Core assets: Cologuard (>5M screened) and Oncotype DX (>2M tests) drive 2024 revenue $3.4B; pipeline multi-cancer blood assays expand TAM. CLIA/CAP labs, validated assays (Cologuard CRC sens 92.1% / spec 86.6%), HEOR, payer coverage >90% and strong provider ties enable adoption.
| Metric | 2024 |
|---|---|
| Revenue | $3.4B |
| Cologuard screened | >5M |
| Oncotype DX tests | >2M |
| Cologuard CRC sens/spec | 92.1% / 86.6% |
| Payer coverage | >90% insured lives |
Value Propositions
Non-invasive early detection
Cologuard is an FDA-approved, stool-based, at-home screening test that is guideline-recommended as a non-invasive option for colorectal cancer screening. The pivotal study reported roughly 92% sensitivity for colorectal cancer, enabling earlier detection that improves outcomes and can lower downstream treatment costs. Convenience of at-home collection boosts adherence versus invasive alternatives, and scalable mail-based programs support population-health screening goals.
Actionable precision oncology
Oncotype DX guides treatment in breast, prostate and colon cancer, translating complex genomics into clear recurrence scores that drive therapy choices. Landmark trials TAILORx and RxPONDER validated its ability to reduce chemotherapy use while preserving outcomes. Broad payer coverage, including Medicare and major commercial plans, reflects evidence-backed clinical utility and payer confidence.
End-to-end diagnostic continuum
Exact Sciences delivers an end-to-end diagnostic continuum with a portfolio spanning screening (Cologuard), molecular diagnosis, and therapy selection, supporting integrated care from detection to treatment planning. Integrated solutions streamline provider workflows and consistent reporting across assays boosts clinical confidence and adoption. Longitudinal data from repeat testing and registries enables ongoing care optimization and population health insights. 2024 revenue was about $3.9 billion, underpinning scale and R&D investment.
High clinical accuracy and trust
Peer-reviewed studies (eg Imperiale et al. 2014) report stool DNA CRC sensitivity 92.3% and specificity 86.6%, with multiple confirmatory real-world validations through 2024. Exact Sciences enforces ISO-like quality systems and lab controls to ensure reproducibility. USPSTF-endorsed stool-based screening options and CMS reimbursement support standard-of-care status, and transparent performance reporting sustains clinician and payer trust.
- Peer-reviewed sensitivity 92.3%
- Specificity 86.6%
- CMS reimbursement = standard-of-care
- Ongoing real-world validations through 2024
Improved patient experience
At-home collection and supportive services lower barriers to colorectal screening by enabling testing outside clinics; Cologuard is FDA-approved and reimbursed by Medicare and many commercial payers, improving access. Clear instructions, reminders and nurse support raise completion and adherence. Fast lab turnaround and financial assistance programs reduce anxiety and out-of-pocket obstacles.
- FDA-approved, Medicare-covered
- At-home collection + reminders = higher completion
- Fast results speed clinical decisions
- Financial assistance lowers cost barriers
FDA-approved at-home CRC test, 92.3% sens, 86.6% spec; $3.9B scale
Cologuard: FDA-approved, at-home CRC screen with 92.3% sensitivity and 86.6% specificity, raising adherence vs colonoscopy. Oncotype DX provides validated recurrence scores that reduce unnecessary chemotherapy. Exact Sciences’ integrated portfolio and 2024 revenue ~$3.9B enable scale, R&D, and payer-supported access.
| Metric | Value |
|---|---|
| 2024 revenue | $3.9B |
| Cologuard sensitivity | 92.3% |
| Cologuard specificity | 86.6% |
| Coverage | Medicare, major payers |
Customer Relationships
Provider education and support
Regular CME programs, webinars, and detailing keep clinicians updated and support adoption across a network that performs over 2 million Cologuard screenings annually; dedicated hotlines and secure portals offer near 24/7 support with sub-24-hour responses for most ordering and interpretation queries. MSLs facilitate more than 1,000 in-depth evidence discussions yearly, and clinician feedback loops have shortened report turnaround and improved tool usability by about 30%.
Payer engagement and value communication
Payer engagement centers on outcome dashboards and HEOR dossiers that supported renewals, contributing to Exact Sciences reporting approximately $2.9B revenue in 2024; contracting teams then tailor coverage terms to align payment with demonstrated value. Joint pilots test population strategies to optimize utilization and cost-effectiveness, while ongoing data sharing—regular claims and outcomes transfers—builds payer trust and sustains coverage.
Patient engagement and adherence
Reminders, apps and mailed prompts drive kit completion, with reminder interventions shown in literature to raise screening adherence by roughly 20–30%; US colorectal cancer screening prevalence was about 67% in 2022 (CDC). Navigation services tackle logistics and clinical questions to remove barriers and reduce no-shows. Multilingual support expands reach to non-English speakers, improving equity. Ongoing satisfaction tracking (Net Promoter/CSAT) feeds iterative UX and outreach improvements.
Health system partnerships
Health system partnerships embed integrated screening pathways that align with system quality metrics and leverage Exact Sciences Cologuard clinical performance (colorectal cancer sensitivity ~92% and specificity ~87% in pivotal studies) to meet screening benchmarks. Bulk provisioning and EHR integration streamline ordering and result flows, reducing administrative burden and supporting population health workflows. Performance reports track screening rates and gaps while joint governance forums oversee outcomes and care pathways.
- Integrated pathways: aligns to quality metrics
- Cologuard performance: sensitivity ~92%, specificity ~87%
- Operations: bulk provisioning + EHR integration
- Oversight: performance reports + joint governance
Research collaborations
Co-development agreements with academic and industry partners drive platform innovation and regulatory-ready assays, enabling Exact Sciences to expand indications; the company cites over 300 peer-reviewed studies supporting its assays as of 2024. Structured data-sharing with clinical networks accelerates biomarker discovery and validation, shortening translational timelines. Publications and conference presentations amplify results and uptake, while long-term collaborations build a continuous pipeline of real-world evidence and cohorts.
- co-development agreements: expand assay scope
- data-sharing: accelerates discovery
- publications/conferences: amplify adoption
- long-term ties: pipeline of real-world evidence
>2M screens/yr, $2.9B revenue via clinician outreach
Clinician engagement via CME, MSLs (>1,000 annual interactions) and 24/7 support sustains adoption across >2M Cologuard screens/year; payer HEOR and pilots helped secure ~$2.9B revenue in 2024. Patient reminders, nav services and multilingual outreach raise adherence ~20–30%; NPS/CSAT guide UX. Health system EHR integration, bulk provisioning and performance reports align screening to quality metrics.
| Metric | Value |
|---|---|
| 2024 revenue | $2.9B |
| Cologuard screens/year | >2,000,000 |
| Sensitivity / Specificity | ~92% / ~87% |
| Peer-reviewed studies (2024) | >300 |
| US CRC screening (2022) | ~67% |
Channels
Direct sales to providers
Field reps and inside sales target primary care, GI, and oncology to drive Cologuard adoption, supported by in-office education and materials; Exact Sciences reported $3.18 billion revenue in 2024, underpinning this commercial investment. Sampling logistics are coordinated directly with providers, and dedicated account management sustains long-term utilization and repeat ordering.
EHR and e-ordering integrations
Embedded order sets in Exact Sciences integrations with major EHRs like Epic and Cerner simplify test selection and standardize workflows. Clinical decision support prompts eligible patients at point of care, driving appropriate screening uptake. Electronic results flow directly into charts, reducing friction and lowering documentation errors. Over 90% of US hospitals used EHRs as of 2024, amplifying reach.
Payer and health system contracts
Formulary placement and diagnostic pathways drive Cologuard volume by channeling patients through covered, preferred screening options; as of 2024 USPSTF recommends colorectal screening from age 45, expanding eligible populations. Population health programs set screening targets and outreach to boost adherence. Value-based arrangements with payers and health systems align incentives around detection and cost savings, and preferred status measurably increases share of screening orders.
Digital and patient-direct outreach
Digital and patient-direct outreach drives Cologuard uptake through targeted online campaigns that raise awareness and prompt screenings; Exact Sciences reported Cologuard cumulative tests exceeding 8 million by 2024. Patient portals automate reminders and status tracking to boost adherence, telehealth partnerships expand access into underserved markets, and educational content supports informed screening choices.
- online campaigns: awareness-to-order conversion
- patient portals: automated reminders, status tracking
- telehealth: expanded access, referral integration
- education: informed consent and adherence
Partnerships with advocacy groups
Partnerships with advocacy groups drive community events and campaigns that have been shown to raise screening uptake—mailed outreach and community programs increase colorectal screening by roughly 15–20 percentage points in controlled studies; co-branded materials with trusted organizations improve credibility and patient trust, boosting kit return rates and clinician referrals.
Field reps, EHRs & patient-direct channels boost stool DNA screening; $3.18B
Field reps/inside sales, EHR integrations, payor/formulary access and digital patient-direct channels drive Cologuard adoption; Exact Sciences revenue $3.18B and >8M cumulative tests (2024) support scale. USPSTF screening from age 45 and >90% US hospitals on EHRs expand addressable market. Community/telehealth outreach raises screening +15–20 pp and boosts kit returns.
| Channel | Key metric | 2024 datapoint |
|---|---|---|
| Sales/Education | Revenue | $3.18B |
| Digital/Patient-direct | Cumulative tests | >8M |
| EHR/Clinical | Hospital EHR adoption | >90% |
| Community/Telehealth | Screening lift | +15–20 pp |
Customer Segments
Primary care and GI providers
Primary care and GI providers are the main prescribers for colorectal screening, guided by USPSTF recommendations for ages 45–75 and quality programs like MIPS; they prioritize easy workflows, proven accuracy and fast, reliable turnaround. Cologuard’s pivotal data show ~92% sensitivity and ~87% specificity for CRC, supporting provider preference for dependable noninvasive options.
Oncologists and tumor boards
Oncologists and tumor boards use precision tests to tailor therapy, seeking validated, actionable results that change management in roughly 30% of cases per 2024 studies. Reports must integrate into multidisciplinary workflows and tumor board presentations for timely decisions. They are highly sensitive to payer coverage and test turnaround time, which directly affect adoption. Decisions prioritize clinical validation and reimbursement certainty.
Payers and health plans
Payers and health plans prioritize cost-effectiveness and measurable outcomes, especially for colorectal cancer screening where CDC data show 68.8% of eligible adults were up to date in 2020. Medicare and many commercial plans cover stool‑based tests, so plans seek predictable pricing, quality guarantees, and programs to boost population screening adherence. Real‑world evidence and outcomes data drive coverage and reimbursement decisions.
Health systems and ACOs
- Scalability: enterprise deployments
- EHR/reporting: real-time integration
- Value-based: measurable outcomes, cost savings
- Vendor: uptime, clinical support, SLAs
Patients at risk for cancer
Patients at risk for cancer need convenient, affordable testing with clear instructions and support; they want quick, trustworthy results and inclusive access across diverse populations. In the US, colorectal cancer remains the third leading cause of cancer death and USPSTF recommends screening for ages 45–75, reinforcing demand for accessible diagnostics. Exact Sciences must prioritize cost, clarity, speed, and equity.
- Require: low-cost, at-home options
- Support: clear instructions, clinician access
- Outcomes: fast, validated results
- Access: address language, socioeconomic, geographic gaps
Noninvasive CRC tests (92% sens/87% spec) and at‑home access drive payer value
Primary care/GI prefer easy workflows and validated noninvasive tests (Cologuard ~92% sensitivity/~87% specificity); oncologists want actionable precision diagnostics that change management (~30% impact). Payers/ACOs demand cost‑effectiveness and outcomes; Exact Sciences 2024 revenue ~4.02B supports scale. Patients seek low‑cost at‑home access, fast results, equity; US CRC screening ~68.8% (2020).
| Segment | Key needs | 2024 metric |
|---|---|---|
| Providers | Accuracy, workflow | 92%/87% |
| Payers/ACOs | Cost/outcomes | 4.02B rev |
| Patients | Access/speed | 68.8% screening |
Cost Structure
R&D and clinical evidence spend
Biomarker discovery, trials, and publications at Exact Sciences require sustained investment, reflected in 2024 R&D spend of about $597 million, funding discovery and multi-phase trials. Regulatory submissions and post-market studies add significant costs, with ongoing clinical program commitments across indications. HEOR and data science teams are core expenses supporting reimbursement and real-world evidence. Pipeline breadth—dozens of programs—drives recurring spend.
Laboratory operations and COGS
Reagents, consumables and instrumentation constitute the primary variable COGS for Exact Sciences, driven by per-test material inputs and instrument depreciation. Labor, regulatory quality systems and facility overhead create fixed-cost tiers supporting lab operations. Kit distribution and sample logistics are material line items, representing significant per-unit fulfillment costs. Automation and scale reduce unit costs—Exact Sciences reported $4.31 billion revenue in 2024, enabling leverage of fixed automation investments.
Sales, marketing, and education
Exact Sciences allocated about $1.2 billion to sales, marketing, and education in 2024, funding a large field force and MSL fleet plus national campaigns that drive adoption and require high recurring spend. Provider and patient materials (brochures, test kits, training) create ongoing per-unit and replenishment costs. Conferences and KOL programs add multi‑million dollar annual investments, while digital tools and EHR integrations require continuous maintenance and platform upgrades.
Regulatory, compliance, and quality
Maintaining CLIA/CAP accreditation and responding to audits requires dedicated personnel and external fees, often costing diagnostics firms millions annually; data privacy and cybersecurity investments rose sharply through 2024 as health-sector threats grew; legal/IP protection and insurance add material recurring expenses; ongoing risk management and staff training are continuous commitments.
- Accreditation/audits: millions annually
- Cybersecurity & privacy: major recurring investment (2024 increase)
- Legal, IP, insurance: significant operating costs
- Risk mgmt & training: continuous, workforce-wide
General and administrative
General and administrative expenses fund corporate functions that support Exact Sciences' global operations, with facilities, IT and HR forming the bulk of overhead; reported SG&A in 2024 was approximately $1.2 billion, driven by scale-up and integration costs.
Insurance and professional services add material, variable costs, and international expansion in 2024 increased compliance and infrastructure spend, raising G&A complexity and cross-border coordination needs.
- 2024-SG&A: ~$1.2B
- Major overhead: facilities, IT, HR
- Additional: insurance, legal, consulting
- International: higher compliance and systems costs
R&D led cost profile: $597M R&D vs $4.31B revenue
R&D led costs (2024 R&D ~$597M) and multi‑phase trials drive high fixed investment; pipeline breadth sustains recurring discovery spend. Variable COGS from reagents, kits and logistics scale down with automation against 2024 revenue of $4.31B. SG&A (~$1.2B in 2024) and accreditation, cybersecurity, legal and international compliance are material recurring overheads.
| Metric | 2024 |
|---|---|
| Revenue | $4.31B |
| R&D | $597M |
| SG&A | $1.2B |
Revenue Streams
Test kits and processing fees
Per-test revenue from Cologuard and related assays is Exact Sciences primary income stream, with Cologuard list price reported at $649 as of 2024; actual realized pricing varies by payer contracts and reimbursements. Volume growth is closely tied to screening adherence and provider uptake, while the guideline-recommended repeat screening interval of every 3 years for Cologuard drives recurring sales.
Precision oncology testing
Oncotype DX generates per-report revenue as a core precision oncology stream, with uptake driven by guideline inclusion and payer coverage; in 2024 this testing remained a key contributor to Exact Sciences' diagnostics revenue. Reimbursement variability and guideline updates directly affect test volumes and average revenue per report. International expansion into new markets provides incremental growth, while approvals for new indications expand the addressable market and lifetime patient testing opportunities.
Value-based and risk-sharing contracts
Outcomes-linked payments align Exact Sciences with payer goals by tying reimbursements to screening uptake, diagnostic yield and avoided downstream costs, supporting bonuses for patient adherence or net savings. Pilots are structured to scale into multi-year risk-sharing deals contingent on demonstrable clinical and economic outcomes. Successful execution requires robust, near-real-time data reporting and analytics to validate performance and trigger payments.
International markets
- Ex-US channels: partners + owned
- 2024 total revenue: ~$2.85B
- Local approvals/reimbursement unlock demand
- Currency/pricing impact yield
- Regional guidelines drive uptake
Data and research collaborations
Grants, sponsored studies and biopharma partnerships fund Exact Sciences’ research; the company reported roughly $3.4 billion revenue in 2023 and expanded collaborative studies into 2024 to scale evidence generation.
De‑identified data projects create ancillary revenue, co‑development milestones deliver upside, and strict governance (HIPAA, IRB oversight, data use agreements) maintains compliance.
- Grants/sponsored studies: external funding
- Biopharma partnerships: milestone + royalty upside
- De‑identified data: ancillary revenue stream
- Governance: HIPAA, IRB, DUA
Per-test stool DNA at $649 drove ~$2.85B 2024 revenue
Per-test Cologuard sales (list price $649 in 2024) and Oncotype DX reports form the core per-test revenue, with volumes tied to guideline adoption and payer coverage. Outcomes-linked contracts and biopharma milestones add performance and milestone-based payments. International expansion and reimbursements drove 2024 revenue mix and margins.
| Metric | 2024 |
|---|---|
| Total revenue | ~$2.85B |
| Cologuard list price | $649 |
| Reported 2023 revenue | $3.4B |
| Cologuard repeat interval | 3 years |